CTLA4 and neoplasm: Nanomaterials can serve as targeted delivery platforms for immune checkpoint inhibitors (such as antibodies against PD-1, PD-L1, and CTLA-4), enabling their precise localization within the tumor microenvironment and enhancing antitumor immune responses [137].